metricas
covid
Clinics Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus d...
Journal Information

Statistics

Follow this link to access the full text of the article

Original articles
Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer
Qi Liua, Lingli Houb,
Corresponding author
845430552@qq.com

Corresponding author.
, Ying Zhaob, Hongwei Yangb, Zhengying Moc, Fei Yud
a Department of Human Anatomy, School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, PR China
b Department of Clinical Laboratory, Taihe Hospital, Affiliated Hospital of Hubei University of Medicine, Shiyan, PR China
c Department of Oncology, Taihe Hospital, Affiliated Hospital of Hubei University of Medicine, Shiyan, PR China
d Department of Clinical Laboratory, People's Hospital of Yunxi County, Yunxi, PR China
Read
1606
Times
was read the article
384
Total PDF
1222
Total HTML
Share statistics
Article information
ISSN: 18075932
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2025 12 8 9 17
2025 11 234 66 300
2025 10 45 27 72
2025 9 55 15 70
2025 8 46 12 58
2025 7 85 7 92
2025 6 37 1 38
2025 5 45 1 46
2025 4 57 2 59
2025 3 29 1 30
2025 2 53 4 57
2025 1 20 2 22
2024 12 27 3 30
2024 11 46 16 62
2024 10 39 18 57
2024 9 53 17 70
2024 8 41 19 60
2024 7 38 23 61
2024 6 36 14 50
2024 5 46 30 76
2024 4 45 19 64
2024 3 29 12 41
2024 2 20 16 36
2024 1 62 20 82
2023 12 26 30 56
Show all

Follow this link to access the full text of the article